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A B S T R A C T
New antimalarial agents are identiﬁed and developed after extensive testing on Plasmodium falciparum parasites
that can be grown in vitro. These susceptibility studies are important to inform lead optimisation and support
further drug development. Until recently, little was known about the susceptibility of non-falciparum species as
these had not been adapted to in vitro culture. The recent culture adaptation of P. knowlesi has therefore oﬀered
an opportunity to routinely deﬁne the drug susceptibility of this species, which is phylogenetically closer to all
other human malarias than is P. falciparum. We compared the in vitro susceptibility of P. knowlesi and P. falci-
parum to a range of established and novel antimalarial agents under identical assay conditions. We demonstrated
that P. knowlesi is signiﬁcantly less susceptible than P. falciparum to six of the compounds tested; and notably
these include three ATP4 inhibitors currently under development as novel antimalarial agents, and one in-
vestigational antimalarial, AN13762, which is 67 fold less eﬀective against P. knowlesi. For the other compounds
there was a less than two-fold diﬀerence in susceptibility between species. We then compared the susceptibility
of a recent P. knowlesi isolate, UM01, to that of the well-established, older A1-H.1 clone. This recent isolate
showed similar in vitro drug susceptibility to the A1-H.1 clone, supporting the ongoing use of the better char-
acterised clone to further study drug susceptibility. Lastly, we used isobologram analysis to explore the inter-
action of a selection of drug combinations and showed similar drug interactions across species. The species
diﬀerences in drug susceptibility reported by us here and previously, support adding in vitro drug screens against
P. knowlesi to those using P. falciparum strains to inform new drug discovery and lead optimisation.
1. Introduction
Since the turn of the century, advances in molecular approaches
have revealed the existence of several zoonotic malaria species world-
wide including; Plasmodium knowlesi (Singh et al., 2004), Plasmodium
brasilianum (Lalremruata et al., 2015), Plasmodium cynomolgi (Ta et al.,
2014) and Plasmodium simium (Brasil et al., 2017). Currently, P.
knowlesi is the most important to human health as it has been shown to
cause severe and fatal disease (Cox-Singh et al., 2008), has a 24 h life
cycle, and is widespread in Asia, being the most prevalent cause of
human malaria infection in Malaysia in 2014. (WHO, 2015a). An ideal
antimalarial agent should kill all human-infecting malaria species.
Current guidelines for non-falciparum malaria species recommend Ar-
temisinin-based Combination Therapies (ACTs). Alternatively,
chloroquine may also be used where a deﬁnitive species diagnosis can
be made, and in areas where there is no evidence of chloroquine re-
sistance (WHO, 2015b). Unfortunately, there is a dearth of information
on drug susceptibility of non-falciparum malarias as we lack in vitro
models to perform large-scale drug screens. However, P. knowlesi has
recently been successfully adapted to long-term in vitro asexual blood
stage culture (Gruring et al., 2014; Lim et al., 2013; Moon et al., 2013)
making it possible to study drug susceptibility in detail, as is routinely
done with P. falciparum.
Previous researchers have reported similar susceptibilities to anti-
malarial agents between P. falciparum and P. knowlesi in vitro (Arnold
et al., 2016; Fatih et al., 2013; Paul et al., 2016). However, our recent
study comparing P. falciparum and P. knowlesi in vitro under identical
conditions identiﬁed signiﬁcant diﬀerences in the susceptibility to
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dihydrofolate reductase (DHFR) inhibitors and dihydroorotate dehy-
drogenase (DHODH) inhibitors (van Schalkwyk et al., 2017). Several
compounds are progressing through the Medicines for Malaria Venture
(MMV) development pipeline and a number are now in human trials.
Many of these were developed from hits identiﬁed through high-
throughput screens on P. falciparum. The growth of P. knowlesi in vitro
has opened the opportunity for more diverse screens of approved and
experimental antimalarial agents. Importantly, P. knowlesi is more
closely related phylogenetically to all the other human malaria species
than is P. falciparum (Rutledge et al., 2017). P. knowlesi may thus be a
suitable surrogate model for understanding the in vitro drug suscept-
ibility of other non-falciparum malaria species.
In this study, we assess the susceptibility of the culture-adapted P.
knowlesi A1-H.1 line to a range of current and emerging antimalarial
agents, and compare these to the widely-available, drug susceptible P.
falciparum 3D7 line. In addition, we report the drug susceptibility of a
new culture-adapted P. knowlesi line, UM01, isolated from a human host
in Malaysia in 2013 (Amir et al., 2016), and compare its susceptibility
proﬁle with our in vitro A1-H.1 line, which was isolated in the 1960s.
Finally, we use isobologram analysis to demonstrate the in vitro inter-
action of selected antimalarial combinations against P. knowlesi and
compare these to drug interactions in P. falciparum.
2. Material and methods
2.1. Parasite culture
P. falciparum (3D7) and P. knowlesi parasites (A1-H.1 and UM01)
were maintained in culture in RPMI 1640 supplemented with 25mM
HEPES, 25mM Na2HCO3, 10mM D-glucose, 2 mM L-glutamine, 50 mg/
L hypoxanthine, 25mg/L gentamicin sulphate, 5 g/L Albumax II and
10% (v/v) equine serum (Thermo Fisher Scientiﬁc, 26-050-088). The P.
falciparum (3D7) and P. knowlesi (A1-H.1) parasites were grown in
human A+ red blood cells (National Health Blood and Transplant, UK).
The UM01 was grown in erythrocytes fromMacaca fascicularis provided
by the National Institute for Biological Standards and Control (UK) in
K2EDTA vacutainers (Becton Dickinson). Parasites were incubated in
sealed ﬂasks at 37 °C under a culture gas mixture of 96% N2, 3% CO2
and 1% O2.
2.2. Drug assays
Established antimalarial drugs and investigational compounds were
supplied by the Medicines for Malaria Venture, Geneva, Switzerland.
Chloroquine stocks were prepared in sterile distilled water and all other
compounds were dissolved in DMSO.
All experiments were initiated using unsynchronised parasites with
both the parasitaemia and haematocrit set to 1%. Drug susceptibility
assays were set up in 96-well, ﬂat-bottom microplates in a ﬁnal volume
of 200 μL, as described previously (van Schalkwyk et al., 2017). Con-
trols were included for the background ﬂuorescence (0% viability;
parasites exposed to a supralethal 10 μM chloroquine concentration)
and 100% growth (parasites in drug-free wells). The plates were in-
cubated for one complete life cycle (27 h for P. knowlesi or 48 h for P.
falciparum in vitro) at 37 °C in a modular incubation chamber (Billups-
Rothenburg Inc.) under culture gas. Upon termination of the assay, the
plates were stored at −20 °C overnight.
The SYBR green I ﬂuorescent method was used to measure parasite
survival (Bennett et al., 2004; Smilkstein et al., 2004). After the mi-
croplates were thawed, 100 μL from each well was transferred into a
duplicate plate. To this was added 100 μL of SYBR green solution [SYBR
green I (Thermo Fisher Scientiﬁc, S7563), diluted 1:5000 in a lysis
buﬀer made of 20mM Tris, 5mM EDTA, 0.008% (w/v) saponin, 0.08%
(v/v) Triton X-100, pH 7.5]. Plates were stored in the dark for 1 h,
before ﬂuorescence was read at 490 nm excitation and 520 nm emission
wavelengths on a Spectramax M3 microplate reader (Molecular
Devices) (van Schalkwyk et al., 2017). The background ﬂuorescence
(wells with parasites at 0% viability) was subtracted from all drug assay
wells and the parasite proliferation determined as a percentage of the
ﬂuorescence in the drug-free control wells.
2.3. Drug combination studies
The in vitro interaction of a select number of drugs was examined
using ﬁxed-ratio isobolograms, prepared as described previously but
using 3-fold dilutions instead of 2-fold dilutions (Fivelman et al., 2004;
van Schalkwyk et al., 2008). These experiments were also performed
with unsynchronised parasites at a ﬁnal parasitaemia and haematocrit
of 1%, and the SYBR green I ﬂuorescent method used to measure
parasite survival as described above. The Fractional Inhibitory Con-
centrations (FICs) were calculated as described previously (van
Schalkwyk et al., 2008). Drug combinations with FICs less than 0.5 are
considered synergistic, while FICs greater than 2 are antagonistic. FICs
lying between 0.5 and 2 are considered additive (Bell, 2005; Odds,
2003).
2.4. Statistics
P values for comparisons between EC50 values were calculated using
Student's two-tailed t-test for unpaired or paired samples as appro-
priate.
3. Results
3.1. Comparison of the susceptibility of P. knowlesi and P. falciparum to
new and established antimalarial agents
Assays on drug-susceptible P. knowlesi A1-H.1 and P. falciparum 3D7
were performed in identical growth media, with drug exposure for a
single life cycle duration (i.e., 27 h for P. knowlesi and 48 h for P. fal-
ciparum in vitro), and growth measured using the SYBR green I ﬂuor-
escence method as reported previously (van Schalkwyk et al., 2017).
The EC50 values for several experimental and established antimalarial
agents are reported in Table 1. Small diﬀerences in susceptibility be-
tween species could be due to diﬀerences in growth rates or synchro-
nicity of the cultures. Hence, we consider potentially important species
diﬀerences only where there is a more than 3-fold diﬀerence in mean
EC50 between the species.
Six compounds were shown to be more than three-fold less sus-
ceptible (i.e. higher EC50 values) when tested against P. knowlesi than P.
falciparum (Table 1). Three of these (cipargamin, SJ733 and PA21A092)
are inhibitors of the sodium channel ATP4 and all three were ∼6-fold
less potent against P. knowlesi. Cladosporin and pentamidine are over 3-
fold less potent against P. knowlesi than P. falciparum. However, the
largest species diﬀerence was observed with AN13762, which was al-
most 67-fold less potent against P. knowlesi when compared to P. fal-
ciparum.
Conversely, we also identiﬁed three antimalarial compounds
(KAF156, halofantrine and MMV884705) that were greater than 3-fold
more potent (i.e., lower EC50 values) in P. knowlesi than P. falciparum
(Table 1). In particular, KAF156 and MMV884705 were both around
4.5-fold more potent against P. knowlesi.
For most of the other compounds screened there was a less than 2-
fold diﬀerence in susceptibility between species, and most were highly
potent (EC50 < 100 nM: Table 1). Artemisinin-based Combination
Therapies (ACTs), composed of a short-acting artemisinin derivative
and a long-acting partner drug, are the current WHO recommended
ﬁrst-line treatments for uncomplicated P. falciparum malaria. En-
doperoxides, including the aforementioned artemisinin derivatives,
were all highly potent against both species (< 11 nM; Table 1). Among
the artemisinin derivatives, artemisone was the most potent with EC50
values below 1 nM. Furthermore, both synthetic endoperoxides,
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arterolane and artefenomel, exhibited EC50 values below 5 nM. As ex-
pected, deoxyartemisinin, an artemisinin lacking the endoperoxide
bridge necessary for antimalarial potency, was inactive at 10 μM
against both species.
Both isomers of the antibiotic mirincamycin were inactive after a
single life cycle exposure, but were highly potent (< 5 nM) when ex-
posed for multiple life cycles of P. knowlesi and P. falciparum and were
not signiﬁcantly diﬀerent between the two species (Table 1).
3.2. Susceptibility of UM01, a recent ﬁeld-derived P. knowlesi line
Given that all comparisons have thus far focused on the use of a
single culture-adapted P. knowlesi strain ﬁrst isolated in the 1960s, we
next sought to test the validity of these comparisons by additionally
testing a more recent clinical P. knowlesi isolate. The susceptibility of
the new P. knowlesi line UM01 (isolated in 2013 from a patient in
Malaysia (Amir et al., 2016)) to a range of antimalarial agents is shown
in Table 2, and compared to the human red blood cell adapted A1-H.1
line. The UM01 line had not been adapted to grow in human red blood
cells at the time of this study but can be grown short-term in macaque
red blood cells. Access to these cells was limited, resulting in only two
experiments being performed in duplicate for each of the drugs, pre-
cluding statistical analysis in comparisons with the A1-H.1 line. For all
but two antimalarial agents tested, and covering a diverse range of
antimalarial targets, the EC50 values for the UM01 line fell within a
two-fold diﬀerence when compared to the A1-H.1 line (Table 2). For
those falling outside the two-fold diﬀerence in EC50 values, P218 (6.03-
fold) and pyronaridine (2.18-fold), the UM01 line was more susceptible
to both drugs. Importantly, the reduced susceptibility of P. knowlesi to
the ATP4 inhibitors (compared with P. falciparum 3D7 in Table 1) is
conﬁrmed with the UM01 line being 3.5-fold and 4.3-fold less potent
for PA21A092 and cipargamin, respectively. Furthermore, the UM01
line (in macaque red blood cells) is 88-fold less susceptible than 3D7 (in
human red blood cells) to AN13762, compared with the 66-fold re-
duced susceptibility for the A1-H1 line relative to 3D7 (Table 1).
3.3. Drug combination studies (isobolograms) comparing P. knowlesi and P.
falciparum
In order to test whether there were diﬀerences in drug interactions
between the two species, we tested ﬁve antimalarial combinations
against the A1-H.1 strain, compared to Pf3D7, using ﬁxed-ratio
Table 1
Comparison of the in vitro susceptibility of Plasmodium knowlesi (A1-H.1) and Plasmodium falciparum (3D7) exposed to established and investigational antimalarial
agents for one complete life cycle.
Compound EC50 values (nM) Fold diﬀerence (Pk/Pf) p-valuea
P. knowlesi (A1-H.1)
27 h exposure
P. falciparum (3D7)
48 h exposure
P. knowlesi EC50 > 3× P. falciparum EC50
Cipargamin (KAE609) 6.1 ± 0.5 0.89 ± 0.08 6.83 < 0.0001
SJ733 386 ± 34 64.3 ± 4.3 6.00 < 0.0001
PA21A092 63.8 ± 7.6 10.2 ± 1.4 6.25 0.0002
AN13762 2762 ± 296 41.3 ± 3.8 66.88 < 0.0001
Pentamidine 331 ± 20 99 ± 4 3.34 0.0003
Cladosporin 411 ± 134 133 ± 10 3.09 0.0831
P. knowlesi EC50 < 1/3× P. falciparum EC50
KAF156 1.7 ± 0.16 7.9 ± 0.12 0.22 < 0.0001
Halofantrine 0.92 ± 0.25 3.60 ± 0.40 0.31 0.0174
NMT MMV884705 46.2 ± 16 206 ± 44 0.22 0.0266
P. knowlesi EC50 ≈ P. falciparum EC50
New Isoquine 15.9 ± 2.4 11.4 ± 2.38 1.39 0.2474
Bisquinoline 2.2 ± 1.40 2.3 ± 0.94 0.97 0.9715
AQ-13 11.4 ± 2.82 5.1 ± 1.15 2.23 0.1091
Quinidine 38.4 ± 10.5 52.9 ± 10.7 0.73 0.3704
Naphthoquine 117 ± 83 111 ± 23 1.05 0.5544
Methylene Blue 5.38 ± 1.8 3.31 ± 0.7 1.63 0.3543
MMV253 13.0 ± 1.9 7.4 ± 1.5 1.76 0.0810
MMV048 17.2 ± 0.9 29.5 ± 2.5 0.58 0.0103
Cyclohexamide 117 ± 40 188 ± 35 0.62 0.2544
Benzylquine 31.53 ± 10.88 22.05 ± 2.02 1.43 0.3469
WR194965 282 ± 111 539 ± 236 0.52 0.3633
BIX-01294 22.6 ± 4.4 21.2 ± 4.1 1.07 0.8207
Sitamaquine 112 ± 25 72 ± 15 1.56 0.2350
Methotrexate 1991 ± 125 693 ± 48 2.87 0.0006
MK-4815 47.6 ± 6 127 ± 16 0.37 0.0100
MMV688558 17.5 ± 2.0 42.4 ± 1.6 0.41 0.0006
Endoperoxides
Dihydroartemisinin 2.35 ± 0.23 5.16 ± 0.62 0.46 0.0017
Artemisinin 7.39 ± 1.87 11.00 ± 1.32 0.67 0.1667
Artemisone 0.47 ± 0.14 0.72 ± 0.15 0.65 0.2701
Artesunate 10.30 ± 1.9 8.28 ± 1.05 1.24 0.3552
Artemether 4.56 ± 0.55 6.93 ± 0.73 0.66 0.0413
Arterolane (OZ277) 2.27 ± 0.42 4.03 ± 0.59 0.56 0.0407
Artefenomel (OZ439) 4.76 ± 0.40 4.82 ± 0.62 0.99 0.9350
Deoxyartemisinin >10,000 >10,000 N.D. N.D.
Delayed death compounds (multiple life cycle exposure)b
Trans-mirincamycin 2.49 ± 0.56 4.89 ± 1.17 0.51 0.1124
Cis-mirincamycin 2.51 ± 0.64 4.61 ± 1.01 0.54 0.1296
EC50 values report the mean ± SEM from at least 3 experiments, and some up to seven repeats, each performed in duplicate.
a p values are calculated by comparing EC50 values for P. falciparum versus P. knowlesi using Student's two-tailed unpaired t-test.
b Asynchronised parasites were exposed to these compounds for 68 h (P. knowlesi) or 120 h (P. falciparum).
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isobolograms (Fig. 1). Considering the 6-fold reduced susceptibility of
P. knowlesi to ATP4 inhibitors – compared with P. falciparum, and re-
ported in Table 1 – we included two ATP4 inhibitors (cipargamin and
PA21A092) in our combination studies to assess whether their diﬀering
in vitro susceptibility might impact their interaction with other anti-
malarial agents. Previous reports, using diﬀerent methodology to our
ﬁxed-ratio method, had suggested the chloroquine/quinine combina-
tion would be antagonistic in Pf3D7 (Skinner-Adams and Davis, 1999)
and that an artemisinin/quinine combination would be additive (Gupta
et al., 2002). For all of the combinations tested, the Fractional In-
hibitory Concentrations (FICs) observed lay between 0.5 and 2.0 – cut-
oﬀs for synergistic and antagonistic interactions, respectively – sug-
gesting all combinations were additive. However, three combinations
(chloroquine/quinine (Fig. 1B and G), chloroquine/cipargamin (Fig. 1C
and H), and dihydroartemisinin/cipargamin (Fig. 1E and J)) show a
concave bend towards an antagonistic interaction. For the chloroquine/
cipargamin interaction, higher FICs were observed for P. falciparum
(range 1.331–1.800; Fig. 1C) than for P. knowlesi (range 1.165–1.428;
Fig. 1H). The combination of dihydroartemisinin with quinine was very
similar between species with all FICs lying between 0.887 and 1.047 for
P. falciparum, and 1.001–1.072 for P. knowlesi (Fig. 1A and F, respec-
tively). When examining the combination of the two selected ATP4
inhibitors, cipargamin and PA21A092, lower FICs were observed with
P. falciparum (range 0.724–1.048; Fig. 1E) compared with P. knowlesi
(range 0.939–1.024; Fig. 1J), suggesting an additive interaction against
both species.
4. Discussion
This study extends our previous observations deﬁning the in vitro
drug susceptibility of the zoonotic parasite P. knowlesi to a range of
antimalarial agents and reveals key diﬀerences when compared to the
Table 2
Comparison of the susceptibility of the culture-adapted P. knowlesi A1-H.1 line
with a recent Malaysian P. knowlesi isolate, UM01.
Compound a UM01
(macaque RBC)
EC50 (nM)
(range/2)
b A1-H.1 (human
RBC) EC50
(nM) ± SEM
Fold diﬀerence
(A1-H.1/
UM01)
Endoperoxides
Dihydroartemisinin 2.1 (0.4) 2.0 ± 0.3 0.95
Artesunate 13.8 (3.6) 10.9 ± 1.7 0.79
Artefenomel (OZ439) 4.4 (1.6) 6.6 ± 1.4 1.5
Quinolines and amino-alcohols
Chloroquine 21.5 (4.9) 29.3 ± 4.7 1.36
Meﬂoquine 13.1 (2.5) 10.9 ± 1.7 0.83
Quinine 40.3 (0.4) 54.8 ± 3.0 1.36
Ferroquine 9.8 (2.32) 12.2 ± 1.6 1.24
Dihydrofolate reductase inhibitors
Pyrimethamine 3.2 (0.5) 5.1 ± 0.8 1.59
Cycloguanil 0.7 (0.1) 1.3 ± 0.3 1.86
Trimethoprim 137 (54) 265 ± 47 1.93
P218 0.68 (0.04) 4.1 ± 0.7 6.03
Other
Atovaquone 4.1 (0.04) 2.6 ± 0.4 0.63
Pyronaridine 4.9 (0.84) 10.7 ± 1.6 2.18
DSM265 170 (66) 303 ± 15 1.78
DSM421 142 (71) 194 ± 23 1.37
Cipargamin (KAE609) 3.8 (1.6) 6.1 ± 0.5 1.61
PA21A092 35.7 (2.8) 63.8 ± 7.6 1.79
AN13762 3618 (110) 2762 ± 296 0.76
Parasites were exposed to the compounds for a single life cycle (27 h).
a UM01 data are the mean of two independent experiments each performed
in duplicate. The range/2, calculated for the two experiments, is shown in
parentheses.
b Data reported previously (van Schalkwyk et al., 2017) or from Table 1
above. Data are the mean ± SEM for at least three experiments each performed
in duplicate.
Fig. 1. Comparison of the in vitro interaction of select antimalarial agents
against Plasmodium falciparum (clone 3D7; panels A to E) and Plasmodium
knowlesi (clone A1-H.1; panels F to J). Isobolograms demonstrate the interac-
tion of quinine with dihydroartemisinin (Panels A and F), quinine with chlor-
oquine (Panels B and G), the spiroindolone, cipargamin, with chloroquine
(panels C to H), cipargamin with PA21A092 (panels D and I), and cipargamin
with dihydroartemisinin (panels E and J). The FIC data are averaged from three
or four independent experiments, each run in triplicate. Error bars represent
standard error of the mean (SEM). FIC values lying between 0.5 and 2.0 are
additive (i.e., no interaction). FIC values below 0.5 are considered synergistic
interactions, while FIC values above 2.0 are considered antagonistic (cut-oﬀs
shown using dotted lines) (Odds, 2003).
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P. falciparum line, 3D7 (van Schalkwyk et al., 2017). The high serum
concentration (10%) in the RPMI 1640-based growth media needed to
support our P. knowlesi growth can impact on the EC50 values of drugs
that are highly protein bound. Hence, our testing of the widely avail-
able P. falciparum (3D7) control line under identical conditions is es-
sential to compare species, and to relate our data to previously reported
EC50 values obtained in other laboratories using diﬀerent media com-
position, assay conditions, and readout.
We previously showed that P. knowlesi is less susceptible than P.
falciparum to several inhibitors of the DHODH enzyme (DSM1,
DSM265, DSM421) (van Schalkwyk et al., 2017). We now extend that
observation to inhibitors of ATP4. Cipargamin (a spiroindolone),
PA21A092 (pyrazoleamide) and SJ733 (dihydroisoquinolone) are che-
mically distinct entities shown to disrupt sodium homeostasis in P.
falciparum (Jimenez-Diaz et al., 2014; Spillman et al., 2013; Vaidya
et al., 2014). Mutations in ATP4 are associated with resistance to these
compounds. Both our P. knowlesi lines (A1-H.1 and UM01) are 3.5–6.8-
fold less susceptible to these compounds than our P. falciparum control
line (Tables 1 and 2). Although the diﬀerences in the A1-H.1 line are
signiﬁcant and apply across the three chemical structures, the com-
pounds can still be considered potent against P. knowlesi
(EC50 < 100 nM for cipargamin and PA21A092), with the clinical
signiﬁcance of these diﬀerences so far unknown. Recent evidence has
suggested that a further 28 compounds within the ‘Malaria Box’ may
inhibit PfATP4 (Lehane et al., 2014). It will therefore be important to
screen these other inhibitors of ATP4, from diverse chemical scaﬀolds,
to establish if the reduced susceptibility in P. knowlesi is maintained
relative to P. falciparum.
Furthermore, P. knowlesi is phylogenetically closer to all other
human-infecting malaria species than is P. falciparum. If this reduced
susceptibility to ATP4 inhibitors is present in other non-falciparum
species then this may have important implications for drug develop-
ment. Fortunately, studies so far have suggested P. vivax is similarly
susceptible to cipargamin as P. falciparum ex vivo (Rottmann et al.,
2010), and that PA21A092 was more potent against P. vivax than P.
falciparum ex vivo (Vaidya et al., 2014). However, three rodent malaria
species were less susceptible to SJ733 than P. falciparum (Jimenez-Diaz
et al., 2014). Clearly, understanding the mechanism responsible for
these species diﬀerences is vital, and is currently the subject of ongoing
research in our laboratory.
Cladosporin targets the lysyl t-RNA synthetase and is > 100-fold
more potent against P. falciparum than the human enzyme (Hoepfner
et al., 2012). Attempts to optimise this target for antimalarial devel-
opment should include screens against P. knowlesi which we show to be
less susceptible in vitro than P. falciparum.
The large diﬀerence in the susceptibility to AN13762 of both P.
knowlesi lines relative to 3D7 (67-fold and 88-fold for A1-H.1 and UM01
lines, respectively) suggest substantial diﬀerences in the potential
target, or perhaps a species-speciﬁc resistance mechanism. The targets
of AN13762 and pentamidine are unknown at present but identifying
these will be crucial to understanding the mechanism and/or genetic
target diﬀerences between the two species responsible for the reduced
susceptibility of P. knowlesi, and whether this extends to other species.
Of less concern (from a therapeutic perspective) are the compounds
showing increased susceptibility in P. knowlesi than P. falciparum. We
have shown that DHFR inhibitors (pyrimethamine, cycloguanil and
trimethoprim) are around 10-fold more potent against P. knowlesi than
P. falciparum (van Schalkwyk et al., 2017). Here, we show also that the
N-methyl transferase inhibitor, MMV884805, and KAF156 were both
4.5 fold more potent against P. knowlesi. Similar to our ﬁndings for
meﬂoquine (van Schalkwyk et al., 2017), P. knowlesi was signiﬁcantly
more susceptible to halofantrine than P. falciparum. A previous study,
using a short term ex vivo schizont maturation approach, reported that
P. knowlesi (six isolates) was four times less susceptible than P. falci-
parum (one isolate) to meﬂoquine (Fatih et al., 2013). In contrast, our
data using directly comparable in vitro assay conditions (parasitaemia,
haematocrit, single life cycle exposure) and SYBR green I readout,
suggest that P. knowlesi is more susceptible than P. falciparum to several
amino-alcohols (meﬂoquine, halofantrine, and lumefantrine) (Table 1
and (van Schalkwyk et al., 2017)). Adapting more P. knowlesi isolates
from the ﬁeld (such as UM01) to in vitro culture will facilitate further
tests to conﬁrm this observation.
Most antimalarial compounds tested were equipotent against both
species (Table 1). These compounds inhibit diverse targets such as
haemozoin formation (AQ-13, MK4815, and quinidine), histone methyl
transferase (BIX-01294), the V-type H+-ATPase (MMV253) and coen-
zyme A biosynthesis (MMV688558). Furthermore, all artemisinin de-
rivatives and synthetic endoperoxides were potent against P. knowlesi.
We have shown previously that the lincosamide antibiotic, clin-
damycin, was highly potent against both P. knowlesi (15.9 nM) and P.
falciparum (7.0 nM) when exposed across multiple life cycles, a phe-
nomenon known as the delayed death eﬀect (van Schalkwyk et al.,
2017). Another lincosamide, mirincamycin, was reported to be more
potent than clindamycin against P. falciparum lines and its activity
shown to be independent of the isomers tested (Held et al., 2010). We
conﬁrm here that mirincamycin is more potent than clindamycin
against P. falciparum 3D7, and demonstrate that it is also more potent
against P. knowlesi A1-H.1 (all < 5 nM; Table 1). Again, this potency is
independent of the isomers being screened.
There may be questions about the applicability of using the P.
knowlesi A1-H.1 line, isolated from a human infection in 1963, to re-
present modern P. knowlesi parasites in drug susceptibility screens. In
Table 2 we report the similarity in drug susceptibility between the “old”
P. knowlesi parasites and our newer isolate, UM01. For most compounds
tested, the EC50 values are lower for the UM01 line, perhaps because
this line is not yet well-adapted to grow in vitro. UM01 only grows in
macaque red blood cells and has 2-fold growth rate per life cycle
compared with the 3–4 fold growth rate of the A1-H.1 line in human
red blood cells. Nevertheless, the similar susceptibility proﬁle of the
UM01 line to the A1-H.1 line for endoperoxides and quinoline-based
drugs is encouraging. Crucially, the reduced susceptibility – relative to
P. falciparum – of the A1-H.1 line to the ATP4 inhibitors cipargamin and
PA21A092, the DHODH inhibitors, DSM265 and DSM421 (reported in
van Schalkwyk et al., 2017) and for AN13762 (Table 1) is conﬁrmed
here also for the UM01 line.
The similar susceptibility proﬁle of our human red blood cell
adapted A1-H.1 line to diverse antimalarial agents, when compared
with a recent ﬁeld isolate, UM01 (Table 2), supports its ongoing use in
screens for antimalarial activity in spite of laboratory propagation since
its origin in the 1960s. Once the UM01 line is culture-adapted to growth
eﬃciently in in vitro human red cells, it will provide a viable alternative
strain to more extensively compare drug susceptibility proﬁles. How-
ever, until that time, we are conﬁdent that the drug susceptibility re-
ported for the A1-H.1 line faithfully represents the current drug sus-
ceptibility proﬁles of circulating P. knowlesi parasites, such as UM01.
To our knowledge, there have not been any published studies
comparing the in vitro interaction of antimalarial agents in P. knowlesi
with that of P. falciparum. Combinations of dihydroartemisinin and
quinine were additive in both species similar to previous reports using
other P. falciparum strains (Gupta et al., 2002). Three combinations;
chloroquine/quinine, chloroquine/cipargamin, and dihy-
droartemisinin/cipargamin, all displayed a weak trend towards antag-
onism against both species. Perhaps surprisingly, the combination of
two ATP4 inhibitors was additive, even tending toward synergism in P.
falciparum. It might be expected that two drugs competing for the same
target might elicit an antagonistic interaction, such as that between
chloroquine and quinine (Skinner-Adams and Davis, 1999). However, it
has been shown previously that mutations in ATP4 conferring re-
sistance to PA21A092 do not elicit cross-resistance to another spir-
oindolone (NITD246). Taken together with the additive eﬀect, this
could suggest these drugs have diﬀerent binding sites within this pu-
tative Na+-ATPase (Vaidya et al., 2014).
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Tremendous strides have been made towards the eradication agenda
with several countries gaining recent WHO certiﬁcation for achieving
malaria elimination (WHO, 2018). However, as progress is made in
reducing the prevalence of P. falciparum and P. vivax malaria, the two
species with the greatest burden of disease, other malarias are taking on
a greater prominence. For example, P. knowlesi incidence was shown to
increase in Malaysia after dramatic reductions in the number of cases
due to P. falciparum and P. vivax (William et al., 2014). It is therefore
imperative that the drug development community is able to test new
compounds for activity against other human malarias to conﬁrm
equipotency and to ensure that new combinations are likely to be ef-
fective. The results presented here begin to address these issues, pro-
viding an in vitro pharmacological characterization of two strains of P.
knowlesi and demonstrating the application of ﬁxed ratio isobologram
analysis for testing drug combinations in P. knowlesi as was done pre-
viously for P. falciparum (Fivelman et al., 2004). Additional testing of
current and novel combinations will now be undertaken.
5. Conclusion
We have identiﬁed further species diﬀerences in drug susceptibility
between P. knowlesi and P. falciparum to select antimalarial classes/
targets (e.g., inhibitors of ATP4 and N-methyltransferase, and as yet
unknown targets of KAF156 and AN13762), in addition to those we
reported previously (van Schalkwyk et al., 2017). Furthermore, we
have shown that the human adapted P. knowlesi A1-H.1 line, used by us
to deﬁne susceptibility to new and established antimalarial agents,
delivers EC50 values similar to a recently isolated P. knowlesi line,
UM01, supporting the continued use of the A1-H.1 line as a model for
testing drug susceptibility in P. knowlesi until new lines can be fully
culture-adapted to human red blood cells. Finally, isobologram analysis
showed that, for a limited selection of antimalarial combinations, drug
interactions were similar between P. knowlesi and P. falciparum in vitro.
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